These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30773174)

  • 1. Outcomes of non-anaplastic stage III and 'inoperable' Wilms tumour treated in the UKW3 trial.
    Irtan S; Messahel B; Moroz V; Taylor RE; Grundy R; Kelsey A; Vujanic G; Pritchard-Jones K;
    Radiother Oncol; 2019 Feb; 131():1-7. PubMed ID: 30773174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study.
    Daw NC; Chi YY; Kim Y; Mullen EA; Kalapurakal JA; Tian J; Khanna G; Geller JI; Perlman EJ; Ehrlich PF; Warwick AB; Grundy PE; Fernandez CV; Dome JS;
    Eur J Cancer; 2019 Sep; 118():58-66. PubMed ID: 31325873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
    J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group.
    Mitchell C; Pritchard-Jones K; Shannon R; Hutton C; Stevens S; Machin D; Imeson J; Kelsey A; Vujanic GM; Gornall P; Walker J; Taylor R; Sartori P; Hale J; Levitt G; Messahel B; Middleton H; Grundy R; Pritchard J;
    Eur J Cancer; 2006 Oct; 42(15):2554-62. PubMed ID: 16904312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.
    Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Acha T; Godzinski J; Oldenburger F; Boccon-Gibod L; Leuschner I; Vujanic G; Sandstedt B; de Kraker J; van Tinteren H; Graf N;
    Lancet; 2015 Sep; 386(9999):1156-64. PubMed ID: 26164096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience.
    Irtan S; Jitlal M; Bate J; Powis M; Vujanic G; Kelsey A; Walker J; Mitchell C; Machin D; Pritchard-Jones K;
    Eur J Cancer; 2015 Jan; 51(2):225-32. PubMed ID: 25465191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children's Cancer Study Group (UKCCSG) study.
    Grundy RG; Hutton C; Middleton H; Imeson J; Pritchard J; Kelsey A; Marsden HB; Vujanic GM; Taylor RE;
    Pediatr Blood Cancer; 2004 Apr; 42(4):311-9. PubMed ID: 14966826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
    Tournade MF; Com-Nougué C; de Kraker J; Ludwig R; Rey A; Burgers JM; Sandstedt B; Godzinski J; Carli M; Potter R; Zucker JM;
    J Clin Oncol; 2001 Jan; 19(2):488-500. PubMed ID: 11208843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
    Spreafico F; Gandola L; D'Angelo P; Terenziani M; Collini P; Bianchi M; Provenzi M; Indolfi P; Pession A; Nantron M; Di Cataldo A; Marchianò A; Catania S; Fossati Bellani F; Piva L;
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):348-54. PubMed ID: 21075548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
    Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral Wilms tumors: Treatment results from a single center.
    Aydın B; Akyüz C; Yalçın B; Ekinci S; Oğuz B; Akçören Z; Yıldız F; Varan A; Kurucu N; Büyükpamukçu M; Kutluk T
    Turk J Pediatr; 2019; 61(1):44-51. PubMed ID: 31559721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms' tumor: the experience of the pediatric unit of Kasr El-Aini center of radiation oncology and nuclear medicine (NEMROCK).
    Abd El-Aal HH; Habib EE; Mishrif MM
    J Egypt Natl Canc Inst; 2005 Dec; 17(4):308-14. PubMed ID: 17102824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial.
    Pritchard-Jones K; Moroz V; Vujanić G; Powis M; Walker J; Messahel B; Hobson R; Levitt G; Kelsey A; Mitchell C
    Ann Oncol; 2012 Sep; 23(9):2457-2463. PubMed ID: 22415585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of advanced Wilms' tumor].
    Li MJ; Huang Y; Tang DX; Zhou YB; Tang HF; Liang JF
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):791-5. PubMed ID: 17366799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor.
    Pachnis A; Pritchard J; Gaze M; Levitt G; Michalski A
    Med Pediatr Oncol; 1998 Sep; 31(3):150-2. PubMed ID: 9722896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.
    Breslow NE; Ou SS; Beckwith JB; Haase GM; Kalapurakal JA; Ritchey ML; Shamberger RC; Thomas PR; D'Angio GJ; Green DM
    Cancer; 2004 Sep; 101(5):1072-80. PubMed ID: 15329918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
    Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
    Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor--lessons and outcomes--a 25-year single center UK experience.
    Fawkner-Corbett DW; Howell L; Pizer BL; Dominici C; McDowell HP; Losty PD
    Pediatr Hematol Oncol; 2014 Aug; 31(5):400-8. PubMed ID: 24933082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Wilms' tumour. Current recommendations.
    Mehta MP; Bastin KT; Wiersma SR
    Drugs; 1991 Nov; 42(5):766-80. PubMed ID: 1723373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.